Sydney-based oncology biotechnology company Kazia Therapeutics (ASX:KZA) formerly known as Novogen, has been recognised at the 2019 Australian and New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation and Growth Awards.
The Awards, which celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand, were presented by New Zealand Prime Minister Jacinda Ardern and Australian trade minister Simon Birmingham at a ceremony in Auckland.
The company is developing cantrixil for the treatment of ovarian cancer and GDC-0084 for the treatment of glioblastoma multiforme.
Kazia was recognised for being an innovative, product-focused and agile company, with the award reflecting the progress it has made in the development of GDC-0084.
The company licensed GDC-0084 from Genentech in 2016 after it demonstrated favourable results in a phase 1 study of 47 patients with advanced brain cancer.